China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
PARSIPPANY, N.J., Feb. 16, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2016 will be released before the market opens on Wednesday, March 1, 2017. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, March 1, 2017, at 8:30 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 40628335.
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 40628335. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
